Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 234 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Qué deben saber los latinos sobre dejar de fumar y las... November 19, 2021 EMA Recommends Granting a Marketing Authorisation for Vorasidenib August 13, 2025 NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 Navigating Life During and After Cancer As a Young Adult: A... November 29, 2022 Load more HOT NEWS Cancer in My Community: The Role of Cancer Screening in Guatemala Women with Diabetes Less Likely to Opt into Cancer Screening, Despite... Are Cancer Patients Getting the Opioids They Need to Control Pain? Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer
